Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free

Samankaltaisia teoksia

• Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
  Tekijä: Coates, L, et al.
  Julkaistu: (2022)
• Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
  Tekijä: Coates, LC, et al.
  Julkaistu: (2024)
• The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
  Tekijä: Ritchlin, CT, et al.
  Julkaistu: (2023)
• Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial
  Tekijä: Orbai, AM, et al.
  Julkaistu: (2021)
• Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phase 3 study
  Tekijä: Orbai, A-M, et al.
  Julkaistu: (2022)